Christakou CD - Search Results

1

Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome.

Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN. Diamanti-Kandarakis E, et al. Among authors: christakou cd. Eur J Endocrinol. 2010 Feb;162(2):193-212. doi: 10.1530/EJE-09-0733. Epub 2009 Oct 19. Eur J Endocrinol. 2010. PMID: 19841045 Review.

2

Does polycystic ovary syndrome start in childhood?

Diamanti-Kandarakis E, Christakou C, Palioura E, Kandaraki E, Livadas S. Diamanti-Kandarakis E, et al. Pediatr Endocrinol Rev. 2008 Jun;5(4):904-11. Pediatr Endocrinol Rev. 2008. PMID: 18552753 Review.

3

Metformin in polycystic ovary syndrome.

Diamanti-Kandarakis E, Economou F, Palimeri S, Christakou C. Diamanti-Kandarakis E, et al. Ann N Y Acad Sci. 2010 Sep;1205:192-8. doi: 10.1111/j.1749-6632.2010.05679.x. Ann N Y Acad Sci. 2010. PMID: 20840272 Review.

4

The pluripotential effects of hypolipidemic treatment for polycystic ovary syndrome (PCOS): dyslipidemia, cardiovascular risk factors and beyond.

Economou F, Xyrafis X, Christakou C, Diamanti-Kandarakis E. Economou F, et al. Curr Pharm Des. 2011;17(9):908-21. doi: 10.2174/138161211795428821. Curr Pharm Des. 2011. PMID: 21418035 Review.

5

Anxiety is associated with hormonal and metabolic profile in women with polycystic ovarian syndrome.

Livadas S, Chaskou S, Kandaraki AA, Skourletos G, Economou F, Christou M, Boutzios G, Karachalios A, Zerva A, Xyrafis X, Christakou C, Pighou AK, Diamanti-Kandarakis E. Livadas S, et al. Clin Endocrinol (Oxf). 2011 Nov;75(5):698-703. doi: 10.1111/j.1365-2265.2011.04122.x. Clin Endocrinol (Oxf). 2011. PMID: 21605157

6

Structural, biochemical and non-traditional cardiovascular risk markers in PCOS.

Christakou C, Diamanti-Kandarakis E. Christakou C, et al. Curr Pharm Des. 2013;19(32):5764-74. doi: 10.2174/1381612811319320011. Curr Pharm Des. 2013. PMID: 23448483 Review.

7

Visceral adiposity index (VAI) is related to the severity of anovulation and other clinical features in women with polycystic ovary syndrome.

Androulakis II, Kandaraki E, Christakou C, Karachalios A, Marinakis E, Paterakis T, Diamanti-Kandarakis E. Androulakis II, et al. Clin Endocrinol (Oxf). 2014 Sep;81(3):426-31. doi: 10.1111/cen.12447. Epub 2014 Apr 15. Clin Endocrinol (Oxf). 2014. PMID: 24601936

8

Polycystic ovary syndrome--phenotypes and diagnosis.

Christakou C, Diamanti-Kandarakis E. Christakou C, et al. Scand J Clin Lab Invest Suppl. 2014;244:18-22; discussion 21. doi: 10.3109/00365513.2014.936675. Scand J Clin Lab Invest Suppl. 2014. PMID: 25083888

9

Early onset adiposity: a pathway to polycystic ovary syndrome in adolescents?

Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Alexandraki KI. Diamanti-Kandarakis E, et al. Among authors: christakou cd. Hormones (Athens). 2007 Jul-Sep;6(3):210-7. Hormones (Athens). 2007. PMID: 17724005 Free article. Review.

10

Role of androgen excess on metabolic aberrations and cardiovascular risk in women with polycystic ovary syndrome.

Christakou CD, Diamanti-Kandarakis E. Christakou CD, et al. Womens Health (Lond). 2008 Nov;4(6):583-94. doi: 10.2217/17455057.4.6.583. Womens Health (Lond). 2008. PMID: 19072461 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

20 results

Search Page